FdaApplication
NDA 021337
Identifiers
- fda_app_no: NDA021337
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2001-11-21 |
Revenue by product
INVANZ
| Period | Revenue |
|---|---|
| Q4 2022 | $41.0M |
| Q3 2022 | $50.0M |
| Q2 2022 | $46.0M |
| Q1 2022 | $52.0M |
| Q4 2021 | $45.0M |
| Q3 2021 | $53.0M |
| Q2 2021 | $48.0M |
| Q1 2021 | $57.0M |
| Q4 2020 | $52.0M |
| Q3 2020 | $51.0M |
| Q2 2020 | $43.0M |
| Q1 2020 | $64.0M |
| Q4 2019 | $57.0M |
| Q3 2019 | $57.0M |
| Q2 2019 | $78.0M |
| Q1 2019 | $72.0M |
| Q4 2018 | $59.0M |
| Q3 2018 | $137.0M |
| Q2 2018 | $149.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INVANZ | ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
1 product